Taking aim at a leading cause of liver failure in the United States, scientists have developed a human monoclonal antibody that neutralizes the Hepatitis C virus. The new antibody effectively neutralized the virus in culture, and then prevented infection by the virus in a pre-clinical animal model of the disease.